Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes

OBJECTIVE — To investigate the metabolic effects of metformin, as compared with placebo, in type 2 diabetic patients intensively treated with insulin.

RESEARCH DESIGN AND METHODS — Metformin improves glycemic control in poorly controlled type 2 diabetic patients. Its effect in type 2 diabetic patients who are intensively treated with insulin has not been studied. A total of 390 patients whose type 2 diabetes was controlled with insulin therapy completed a randomized controlled double-blind trial with a planned interim analysis after 16 weeks of treatment. The subjects were selected from three outpatient clinics in regional hospitals and were randomly assigned to either the placebo or metformin group, in addition to insulin therapy. Intensive glucose monitoring with immediate insulin adjustments according to strict guidelines was conducted. Indices of glycemic control, insulin requirements, body weight, blood pressure, plasma lipids, hypoglycemic events, and other adverse events were measured.

RESULTS — Of the 390 subjects, 37 dropped out (12 in the placebo and 25 in the metformin group). Of those who completed 16 weeks of treatment, metformin use, as compared with placebo, was associated with improved glycemic control (mean daily glucose at 16 weeks 7.8 vs. 8.8 mmol/l, P = 0.006; mean GHb 6.9 vs. 7.6%, P < 0.0001); reduced insulin requirements (63.8 vs. 71.3 IU, P < 0.0001); reduced weight gain (−0.4 vs. +1.2 kg, P < 0.01); and decreased plasma LDL cholesterol (−0.21 vs. −0.02 mmol/l, P < 0.01). Risk of hypoglycemia was similar in both groups.

CONCLUSIONS — In type 2 diabetic patients who are intensively treated with insulin, the combination of insulin and metformin results in superior glycemic control compared with insulin therapy alone, while insulin requirements and weight gain are less.
of age who had received a diagnosis of diabetes after 25 years of age, had never had an episode of ketoacidosis, and whose blood glucose–lowering treatment had previously consisted of oral agents but now exclusively consisted of insulin or a combination of insulin and metformin. We excluded pregnant women and women trying to become pregnant, patients with a Cockcroft-Gault–estimated creatinine clearance <50 ml/min (17) or low plasma cholinesterase (reference value, ≥3.5 units/l) (18), and patients with congestive heart failure (New York Heart Association class III/IV) or other serious medical or psychiatric diseases. All patients gave written informed consent. The medical ethical committees of the three participating hospitals approved the trial protocol. The trial has been and is conducted in accordance with the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) dated 17 July 1996 and in accordance with the Declaration of Helsinki (revised version of Hong Kong, 1989).

Study design
The HOME trial was conducted in the outpatient clinics of three nonacademic hospitals (Hoogeveen, Meppel, and Coevorden). The trial design consisted of three phases (Fig. 1). In the 12-week pre-randomization phase we aimed to optimize glycemic control by intensive glucose monitoring and insulin adjustment (target plasma glucose levels between 4 and 7 mmol/l in the fasting state and between 4 and 10 mmol/l postprandially). All subjects monitored their plasma glucose levels at home every 2 weeks (i.e., just before and ~90 min after breakfast, lunch, and dinner and at bedtime) using the same monitoring device (Glucotouch; Lifescan, Beerse, Belgium). The patients reported these values by telephone to a nurse specialized in diabetes care, who, if necessary, gave advice to adjust the insulin dose or try another insulin mixture or injection schedule. All patients were treated with insulin four times daily (Actrapid preceding the three meals and Insulatard ante noctem; Novo Nordisk, Alphen a/d Ryn, the Netherlands) or twice daily (Mixtures of Actrapid (10–50%) and Insulatard (90–50%) preceding breakfast and dinner: Mixtard preparations; Novo Nordisk). Individual titration took place according to good clinical practice to reach the target glucose levels and to prevent hypoglycemia. The nurse specialized in diabetes care, and if necessary, gave advice to adjust the insulin dose or
try another insulin mixture (e.g., Mixtard 50/50 instead of Mixtard 30/70) or injection schedule (e.g., four times instead of twice daily). The adjustments of the insulin dose took place in “small steps,” changing the dose by ≤4 units per injection. If the target values for glycemic control were difficult to reach, the study nurse consulted the principal investigator for advice to optimize the insulin therapy. This intensive glucose-monitoring and insulin adjustment scheme was continued during the whole trial. The second feature of the prerandomization phase was the discontinuation of concomitant medication for hypertension and dyslipidemia if the patient’s physician approved this.

At the start of the 16-week short-term active treatment phase, all subjects were randomly assigned in a double-blind fashion to receive placebo or metformin in addition to insulin therapy. All patients were numbered in order of study entry and received trial medication with the same number. The boxes and tablets of metformin and placebo had a similar appearance. Each subject successively increased the dose from one to finally three tablets a day, if tolerated. The first tablet was taken at bedtime, the second at breakfast, and the third at dinner. The dose of the metformin tablets was 850 mg, and the actual mean dose in the metformin-treated group was 2,163 mg during the trial. At the beginning and at the end of the short-term active treatment phase, fasting blood samples were drawn, a physical examination was carried out, and a complete medical history was taken. During the prerandomization and short-term active treatment phases, target values for blood pressure, urinary albumin-to-creatinine ratio, and plasma LDL cholesterol concentration were <180/110 mmHg, <100 mg/mmol, and <7.0 mmol/l, respectively, because we wished to study the effects of metformin on these variables in the (near) absence of blood pressure– and cholesterol-lowering treatment. The less-tight blood pressure and cholesterol targets that were thought acceptable according to Dutch guidelines during the development of the study protocol and during the first year of the trial (1996–1997) would not be considered acceptable today (19,20).

The 48-month long-term active treatment phase is a continuation of the short-term active treatment phase. However, in this phase, we aimed for tight control of blood pressure, urinary albumin-to-creatinine ratio, and plasma LDL cholesterol levels (target values <150/90 mmHg, <3.5 mg/mmol in women and <2.5 mg/mmol in men, and <2.6 mmol/l, respectively).

The specified medications used for the treatment of hyperlipidemia were simvastatin and acipimox. The medications used for the treatment of hypertension were enalapril, kaliumlosartan, hydrochlorothiazide, and lercanidipine. Both groups were comparably treated with these drugs according to a specified “add-on protocol” to reach the target values. No significant differences were found between the treatment groups in the use of these concomitant medications. The results presented here exclusively concern the prerandomization and short-term active treatment phases.

**Physical examination**

The same investigator carried out all examinations. We measured blood pressure, weight, height, and waist and hip circumferences and calculated the BMI (kg/m²) and the waist-to-hip ratio (dimensionless). Patients were weighed wearing underclothes. The initial blood pressure measurement was taken at both arms after the patient had sat down for at least 10 min. Follow-up measurements were taken at the side where the highest systolic pressure was noted. We used a mercury sphygmomanometer (Speidel-Keller, miniatur 300) with several cuffs, depending on the size of the subject’s arm.

**Laboratory investigations**

The laboratories of the three hospitals used standard analytical methods with the same reference values for all laboratory variables. Plasma glucose levels were determined using an automated glucose oxidase method (Hitachi 917; Roche, Basel) in Hoogeveen and Meppel. GHb (normal value 4.0–6.0%) was measured by high-performance liquid chromatography in Hoogeveen and by an immunoturbidimetric method (Unimate; Roche) in Meppel. Method comparison according to Passing and Bablok (21,22) showed no significant deviation between these methods. Moreover, by using a randomized Block test on GHb values no significant difference could be found between the laboratories. Fasting lipid and lipoprotein concentrations were assessed by standard methods. Plasma LDL cholesterol was calculated with use of the Friedewald formula if triglycerides were <4.5 mmol/l (23). The Coevorden Hospital used dry chemistry for all the above-mentioned laboratory measurements.

---

**Table 1—Baseline characteristics**

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Placebo</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>182</td>
<td>171</td>
</tr>
<tr>
<td>Men/women</td>
<td>91/91</td>
<td>76/95</td>
</tr>
<tr>
<td>Age (years)</td>
<td>58.9 ± 11.1</td>
<td>63.2 ± 9.8</td>
</tr>
<tr>
<td>Currently smoking</td>
<td>54 (30)</td>
<td>36 (21)</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>12.0 ± 8.0</td>
<td>14.0 ± 8.4</td>
</tr>
<tr>
<td>Insulin treatment (years)</td>
<td>5.7 ± 5.9</td>
<td>6.5 ± 7.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diabetic complications</th>
<th>Placebo</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>53 (29)</td>
<td>50 (35)</td>
</tr>
<tr>
<td>Retinal coagulation and (or) cataract extraction</td>
<td>25 (14)</td>
<td>38 (22)</td>
</tr>
<tr>
<td>Amputation</td>
<td>3 (2)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Paresthesias</td>
<td>79 (43)</td>
<td>83 (49)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Concomitant medication</th>
<th>Placebo</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid-lowering drugs</td>
<td>36 (20)</td>
<td>34 (20)</td>
</tr>
<tr>
<td>Blood pressure–lowering drugs</td>
<td>73 (40)</td>
<td>88 (51)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Placebo</th>
<th>Metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist-to-hip ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>1.03 ± 0.09</td>
<td>1.02 ± 0.08</td>
</tr>
<tr>
<td>Women</td>
<td>0.92 ± 0.09</td>
<td>0.93 ± 0.1</td>
</tr>
</tbody>
</table>

Data are mean ± SD or n (%).
Statistical analysis
A power analysis indicated that 390 patients needed to be randomized to demonstrate a difference in the incidence of micro- and macrovascular events of 8% points between the groups after 4 years of follow-up (one-tailed test with an α of 0.05 and a β of 0.25; expected cumulative incidences of cardiovascular events 20 vs. 12% in the placebo and metformin groups, respectively). However, in this interim analysis the primary end points are GHb and the daily dose of insulin. Secondary end points are BMI, body weight, plasma cholesterol, plasma triglycerides, and blood pressure.

The data presented concern all patients seen at the beginning and the end of the short-term active treatment phase. In addition, we did an intent-to-treat analysis in which we assumed that outcome variables in patients who dropped out did not change between baseline and follow-up. As the HOME-trial is ongoing, the treatment codes were not disclosed to the investigators and were available only to the statistician, who provided only grouped data with means and SD to the investigators. According to the planned protocol, the significance of the effects of metformin, as compared with placebo, on the quantitative end points (plasma glucose levels, GHb, insulin requirement, weight, blood pressure, and plasma lipids) was assessed by analyzing the final value, adjusting for the baseline value through an ANCOVA (24). The \( \chi^2 \) test was used to compare the number of hypoglycemic events between the two treatment groups. Data are expressed as mean (SD) or mean (95% CI). The median and 25th and 75th percentiles are given for insulin dosage. All tests were two-sided and differences with \( P < 0.05 \) were considered to be statistically significant. A supplementary multiple regression analysis was performed with age as covariate and its first order interaction with all outcome variables. Double data entry and statistical analyses were carried out with the SAS package 6.08 on the Windows system.

RESULTS
Patients
We screened the medical files of all three participating outpatient clinics and identified 745 eligible patients. All were approached to enroll into the trial and 390 subjects gave written informed consent (Fig. 2). The subjects were randomized to receive metformin (196 subjects) and placebo (194 subjects). Of the 390 subjects, 37 dropped out, 25 in the metformin and 12 in the placebo group. A total of 2 patients never took their medication (placebo 1, metformin 1), 9 withdrew their consent (placebo 5, metformin 4), and 26 experienced adverse effects (placebo 6, metformin 20). Of these 26, 11 experienced diarrhea (placebo 2, metformin 9),
5 flatulence (placebo 1, metformin 4), 4 fatigue (placebo 1, metformin 3), 1 pruritus (metformin), 1 headaches (metformin), 1 pyrosis (placebo), 1 nausea (metformin), 1 myocardial infarction (placebo), and 1 patient died suddenly (metformin).

Table 1 shows baseline characteristics at the start of the short active treatment phase. Patients randomized to metformin were slightly older than patients randomized to placebo (63.2 ± 9.8 vs. 58.9 ± 11.1 years), but other baseline characteristics were comparable between the two groups.

Glycemic control and daily insulin requirement
In the short-term active treatment phase, plasma glucose values obtained with home monitoring decreased significantly more in the metformin group than in the placebo group (Fig. 3). The mean daily glucose level decreased from 8.8 ± 2.1 to 8.5 ± 1.7 mmol/l in the metformin group (mean decrease −0.16; 95% CI −0.53 to 0.22 mmol/l) and from 8.8 ± 2.2 to 7.8 ± 1.7 mmol/l in the metformin group (P = 0.006 vs. placebo; mean decrease −1.04; 95% CI −1.5 to −0.52 mmol/l). The mean daily glucose level decreased 0.7 mmol/l more in the metformin group than in the placebo group.

Changes in GHb and daily dose of insulin are shown in Table 2. Mean GHb level decreased from 7.9 ± 1.2 to 7.6 ± 1.2% in the placebo group (P = 0.031 vs. baseline; mean decrease −0.27; 95% CI −0.25 to −0.52% point) and from 7.9 ± 1.2 to 6.9 ± 1.0% in the metformin group (P < 0.0001 vs. baseline vs. placebo; mean decrease −0.91; 95% CI −0.69 to −1.15% point). Mean GHb levels decreased 0.6% point more in the metformin than in the placebo group (Table 2). The difference in GHb levels between the metformin and placebo groups was similar in each of the three centers (P for interaction = 0.51, data not shown). The daily dose of insulin increased 1.4 IU (95% CI 0.3–2.9) in the placebo group and decreased 7.2 IU (95% CI −5.8 to −8.8) in the metformin group (P < 0.0001 vs. placebo).

Body weight and BMI
Changes are shown in Table 2. In the placebo group, body weight and BMI increased by +1.2 kg (95% CI 0.4–2.0) and +0.4 kg/m² (95% CI 0.2–0.7), respectively. In the metformin group, body weight and BMI decreased by −0.4 kg (95% CI −0.1 to −0.8) and −0.2 kg/m² (95% CI −0.2 to −0.3), respectively (P < 0.01 vs. placebo for both). Compared with the placebo group, the change in body weight was −1.6 kg and the change in BMI was −0.6 kg/m² in the metformin group.

Blood pressure and plasma lipids
Data are shown in Table 2. There was a small but nonsignificant increase in blood pressure in both groups that did not differ between the groups (Table 2). In the placebo group, plasma total and LDL cholesterol concentrations decreased by −0.04 mmol/l (95% CI −0.15 to 0.07) and −0.02 mmol/l (95% CI −0.16 to 0.06), respectively. In the metformin group, plasma total cholesterol and LDL cholesterol concentrations decreased by −0.25 (95% CI −0.35 to −0.15) and −0.21 mmol/l (95% CI −0.33 to −0.15), respectively (P < 0.01 vs. placebo for both). The differences between the metformin and placebo group were −0.21 mmol/l for total cholesterol and −0.19 mmol/l for LDL cholesterol. LDL cholesterol concentrations were not calculated in patients with triglyceride values >4.5 mmol/l at baseline and/or at follow-up (n = 23 in the placebo and n = 18 in the metformin group). Adjustment for GHb change did not importantly change on the effect estimate of metformin treatment on plasma LDL cholesterol (data not shown). There were no significant changes in plasma HDL cholesterol and triglyceride concentrations in either group (data not shown).

Additional analyses
Secondary analyses were carried out. First, we reanalyzed the same results following the same ANCOVA model but using age as an additional covariate (because age was not totally balanced among groups at baseline). Second, to make sure that the results are independent of the initial intent-to-treat selection, we carried out the same analysis on the full set of patients, where for patients lost after baseline, final values were considered as unchanged with respect to baseline values. For these two supplemental analyses, the results, CIs, and corresponding P values were unchanged.

Adverse events and hypoglycemic incidents
In the short-term active treatment phase, the number of symptomatic hypoglycemic events per patient per month increased from 0.29 ± 0.83 to 1.12 ± 2.67
(P < 0.001) in the placebo group and from 0.86 ± 1.76 to 1.52 ± 4.29 (P = 0.06) in the metformin group (P = 0.29 vs. placebo). The occurrence of none to four or more hypoglycemic events per subject per month was comparable between the groups (none: placebo 123 [68%] vs. metformin 108 [64%]; one: placebo 30 [16%] vs. metformin 31 [18%]; two: placebo 11 [6%] vs. metformin 12 [7%]; three: placebo 11 [6%] vs. metformin 9 [5%]; four or more: placebo 7 [4%] vs. metformin 11 [6%]; χ² P = 0.477). Eight events in the metformin group and four in the control group required partner assistance, and none required medical assistance. Most patients tolerated the trial medication well (metformin 90%; placebo 97%). Mild and transient gastrointestinal complaints were reported most frequently in the metformin group (56%) and less in the placebo group (13%, P < 0.0001 vs. metformin).

**CONCLUSIONS** — We designed this placebo-controlled randomized double-blind trial to test the hypothesis that in individuals with type 2 diabetes who are intensively treated with insulin and reach similar glycemic control, the use of metformin to decrease the required daily dose of exogenous insulin is associated with a
decreased risk of cardiovascular disease. A planned interim analysis after 16 weeks of treatment showed that despite intensive glucose monitoring and frequent adjustment of the insulin dose, metformin use compared with placebo was associated with a statistically significant and potentially clinically relevant improvement of glycemic control (GHB 6.9 vs. 7.6%). Metformin use was also associated with less weight gain (−1.6 kg compared with placebo) and with a small decrease in LDL cholesterol (−0.19 mmol/l). Taken together, these data suggest that metformin may have important advantages in type 2 diabetic patients who are intensively treated with insulin. Our results were obtained in a nonacademic setting and may thus have broad applicability. Others recently suggested advantageous effects of metformin in poorly controlled type 2 diabetic patients treated in academic centers (4,13,14).

It is not clear why we did not achieve our aim of similar glycemic control in both groups. The groups were comparable at baseline, and compliance with the intensive treatment regimen was high. One possibility is that an increased risk of hypoglycemic events in the placebo (insulin only) group prevented further increments in the insulin dose. However, the occurrence of hypoglycemic events did not differ between the metformin and placebo groups (Table 2), and advice to increase the insulin dose was never refused in either group (data not shown). These data suggest that in type 2 diabetic patients treated with insulin, metformin may affect glucose metabolism in a way that is not easily achieved with exogenous insulin, for example by more efficiently reducing hepatic glucose output (25,26). This hypothesis requires further investigation.

Metformin use, compared with placebo, was associated with a 10% decrease of the daily dose of insulin, while glycemic control was better. This reduction in insulin requirement is consistent with that reported in earlier studies of obese type 2 diabetic patients with poor glycemic control (decrease varying from 4 to 25%) (4,13,27). A much longer follow-up is necessary to investigate whether this reduction in exogenous insulin requirement will result in a decreased risk of atherothrombotic disease (28–30). However, if less weight gain will occur, and be maintained during the longer term, in patients treated with less exogenous insulin, it will be difficult to unravel the contributions of weight and insulin dose on the incidence of cardiovascular disease. Therefore, we realize that favorable effects on cardiovascular disease (if any) must then be ascribed to the totality of effects of metformin and cannot be solely ascribed to the decrease in insulin dose. No definitive evidence yet exists that hyperinsulinemia itself is a significant atherothrombotic risk factor.

Our findings confirm a small but significant decrease of plasma LDL cholesterol during metformin treatment (30), which could not be explained by improvement in glycemia (5,31–34). Indeed, some in vitro studies show a direct effect of metformin on cholesterol metabolism (35,36).

In conclusion, our findings show that in type 2 diabetic patients who are intensively treated with insulin, the use of metformin is associated with improved glycemic control, a reduced insulin requirement, less weight gain, and a small decrease in LDL cholesterol levels. Metformin therefore is a valuable treatment option in insulin-treated type 2 diabetic patients.

Acknowledgments—This part of the HOME-trial was supported by grants from Byk, Lifescan, E. Merck Liptha, Merck Sharpe & Dohme, and Novo Nordisk.

We thank the study nurses Liesbeth Breedland and Els van Driessen for their dedication to the concerns of the patients and the quality of the treatments; Van der Kolk for his technical assistance and validation of the laboratory techniques; Gerard de Groot, Rob Hoorn, and Erik Pieterse for their hospitality at their laboratories; and all other members of the HOME-study group for their contribution to the HOME-trial.

References
The HOME-trial: a randomized controlled trial